(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Flu concerns grow in US as UK sees more cases among kids - 2PFAS in pregnant women’s drinking water puts their babies at higher risk, study finds
- 3Nikki Glaser returns as host of the 2026 Golden Globes: Everything the comedian has said about the upcoming awards show
- 4CDC studies show value of nationwide wastewater disease surveillance, as potential funding cut looms
- 5Find the Insider facts of Viable Advertising: Building a Positive Brand Picture
- Planet-eating stars hint at Earth's ultimate fate
- Vote In favor of Your Favored Language Interpretation Administration
- Hilary Duff's husband responds to Ashley Tisdale's 'toxic' mom group claims: The drama, explained
- Smuggler who called migrants 'chickens' jailed
- Over 1,800 killed since junta seized power in Burkina Faso, rights group says
- 5 Affordable Travel Destinations To Visit In South America
- Examination In progress into Abuse of Japanese Government-Supported Advance
- Eli Lilly weight-loss drug appears to suppress binge-eating signal, small study finds
- 6 Trail blazing Bicycles for Rough terrain Undertakings
